DOCSLIB.ORG

Efficacy Trials and Progress of HIV Vaccines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy Trials and Progress of HIV Vaccines ll Scienc Ce e f & o T l h a e n r a r a p p u u y y o o J J Journal of Cell Science & Therapy Asif and Irshad, J Cell Sci Ther 2017, 8:2 ISSN: 2157-7013 DOI: 10.4172/2157-7013. 1000265 Review Article Open Access Efficacy Trials and Progress of HIV Vaccines Daud Faran Asif1*, and Irshad M2 1Department of Biochemistry and Biotechnology, University of Gujrat, Pakistan 2Department of Biotechnology, University of Gujrat, Gujrat, Pakistan *Corresponding author: Daud Faran Asif, BS. Hons Student, Department of Biochemistry and Biotechnology, University of Gujrat, Pakistan, Tel: 92533643112; E-mail: [email protected] Rec date: Mar 18, 2017; Acc date: Apr 01, 2017; Pub date: Apr 04, 2017 Copyright: © 2017 Asif DF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Discovery of HIV as causative agent of AIDS let to the belief that a vaccine for AIDS will be available shortly but was not that easy, and it took more than 30 years of hard laboratory and clinical work toward HIV vaccine development. Efficacy trials of RV144 and their results revealed that HIV vaccine is accomplishable. Clinical trials for developing bNAbs has monoclonal antibodies and to increase its half-life are also underway to achieve a proper HIV vaccine. In this review article, we see that how these efficacy trials are highlighting HIV vaccine concepts in clinical development. Therapeutic vaccines are proving to be a functional cure toward HIV treatment and progress is ongoing in such HIV vaccine development which will attack HIV before it fuses with cell and cause infection thus preventing AIDS. So, in near future it will be possible to cure HIV and bring an end to this epidemic. Keywords: HIV vaccine; Clinical trials; AIDS; Efficacy trials of have a near normal life expectancy. In the first 15-20 years of the RV144 pandemic, during a time when effective ART was unavailable or in its infancy, there was intense scientific interest and inquiry into molecular Introduction mechanisms of HIV replication, in order to develop effective drugs with which to inhibit HIV replication in vivo. In the past 15 years, When HIV (Human Immunodeficiency virus) was discovered and multiple drugs in multiple classes have been developed and much has established as the causative agent of AIDS in 1983-1984 [1], the been learned about how best to use combinations of agents. Now it is majority of people thought that vaccines against this HIV would be possible, and even expected, that clinical viral suppression can be developed and applied rapidly. But, this was not going to happen in achieved, with consequent immune reconstitution. However, treated case of HIV as in AIDS, virus-induced immune response possesses no individuals still have excess morbidity and mortality when compared ability to prevent re-infection and also not capable of slowing down the to uninfected persons, due largely to accelerated aging and age related progression to disease. The development of an HIV vaccine took diseases such as cardiovascular disease, metabolic syndrome solid almost 30 years of intense laboratory and clinical work. And because of organ malignancies, neurocognitive and functional decline and this intense work, today we are closer to develop an HIV vaccine but, it osteoporosis. is difficult to predict the time when we have the vaccine that possesses sufficient efficacy for implementation in public health programs [2]. Development of an HIV Vaccine: A Difficult Challenge Why HIV vaccine is needed? The development of a safe and highly effective vaccine against HIV has been a difficult challenge because of the ability of HIV to escape To stop the spread of AIDS caused by HIV, we have to stop the host immune response. There are three main scientific challenges for occurrence of new HIV infections. For preventing new HIV infections the development of an HIV vaccine. These challenges include following from occurring, several preventive measures are applied, but these [7-9]: preventive measures have some shortcomings, e.g. although condom use and sterile needles have a strong impact, but they possess The immunological correlates of protection against HIV/ insufficient adherence and access that limit their impact [3]. Other AIDS are unknown preventive measures, including male circumcision, pre-prophylaxis (PreP) and Antiretroviral therapy (ART) [4-6] have encountered the In most diseases that are prevented by vaccines, there is a same problems of limited access and adherence. Vaccination does not correlation between the immune responses induced by vaccines and involve such problems so it is preferred over other preventive the protection against disease or infection. But in case of HIV virus in measures. Also, vaccination possesses the ability to eradicate the virus, contrast to this correlation, broad range of immune responses is because of this ability it has been the major goal to develop an HIV developed against HIV in people infected with this virus. These vaccine to prevent new infections from occurring [3]. In the past immune responses are not able to either eradicate the infection or to 33 years of the HIV pandemic, there has been monumental progress in inhibit the progress towards AIDS [10]. The current development the clinical management of HIV disease. Once considered a death strategies of an HIV vaccine are directed at the induction of humoral sentence due to the inexorable decline in CD4 T cell number and and cellular immunity and these strategies, also involve the induction function over time ultimately leading to AIDS, patients with HIV of both major types of immune responses (humoral and cellular). infection who have access to effective antiretroviral therapy (ART) now Although it is a difficult challenge, but it is not an impossible target to J Cell Sci Ther, an open access journal Volume 8 • Issue 2 • 1000265 ISSN: 2157-7013 Citation: Asif DF, Irshad M (2017) Efficacy Trials and Progress of HIV Vaccines. J Cell Sci Ther 8: 265. doi:10.4172/2157-7013. 1000265 Page 2 of 11 achieve. There has been the evidence that the early stages of These earlier trials intended to target at the production of transmission of HIV are susceptible to intervention of immune neutralizing antibodies but in these experiments, difficulties were response [11]. The first experiment involving the immunization of reported with the immunogen. Then the focus of an HIV vaccines humans against HIV-Ι (a strain of HIV) begun in November 1986 turned on to cytotoxic T-lymphocytes (CTLs) [12-17]. Because in involving a sufficient number of HIV healthy volunteers. In this immune system cytotoxic T-lymphocytes play a significant role in experiment, vaccinia virus recombinant (V25) that expresses gp160 controlling the levels of virus during the natural infection of HIV. So, env at the surface of infected cells are applied. gp160 env are the targeting CTLs has also been a preference for research and determinants of HTLVΙΙΙB. The results of this experiment showed that development of HIV vaccine [3]. The development of an HIV vaccine the immune response against HIV can be achieved in humans [12]. is a difficult challenge because of lengthy, time consuming and Following this experiment, almost more than 256 clinical trials (phase expensive clinical trials for testing HIV candidate vaccines. In spite of Ι and phase ΙΙ) including over 44, 000 healthy volunteers have tested the difficult and enormous challenge, the recent success provides a way candidate vaccines against HIV [12-17]. Among these clinical trials, forward towards the development of vaccine against HIV [3] (Table 1). only six candidate vaccines have achieved clinical efficacy. These six vaccines include VAX004, VAX003, Phambali, HVTN505 and RV144 [18]. HIV vaccine efficacy trial Expected immune Trial Name Trial duration Phase type Type of vaccine Outcome response VAX004 1998-2003 ΙΙΙ rpg120 (clade B) Humoral No efficacy VAX003 1999-2003 ΙΙΙ rgp120 (clades B+E) Humoral No efficacy Enhanced HIV infection risk 2004-2007 (Stopped for possible Step ΙΙb Cellular in uncircumcised men and enhancement in HIV acquisition) MSM Phambili 2007 ΙΙb rAD5 (gag/pollnef) Cellular No efficacy Cellular along with RV 144 2003-2009 ΙΙΙ Canarypox (gag/pollnef) 31.2% efficacy humoral DNA Humoral as well as HTVN 505 2009-2015 ΙΙb No efficacy plasmid (gag/pollneflenv) cellular +rAD5 (gag/pollen) Table 1: Illustrating the trials of different HIV vaccines and their outcomes [18; p3]. Presence of genetic variability in HIV The deficit of appropriate animal models The genetic analysis of HIV strains that are isolated from different Many experimental HIV vaccines have produced different parts of the world has disclosed that many genes present in HIV intensities of protection in non-human primate models involving display wide sequence heterogeneity specifically in the genes that Chimpanzees that are exposed with HIV and monkeys that are encode viral envelope proteins gp120 and gp41. As a result of this exposed to SIV; an analogous to HIV. The basic problem is that heterogeneity, the strains of HIV-Ι are divided into groups and different experiment vaccines generate dissimilar results in these two subtypes. Most of HIV infection are caused by viruses of HIV-Ι group models involving chimpanzees and monkeys. It is also not clear that M that is further divided into 9 subtypes from A-J. There is also a the results from these models would predict vaccine induced chance of generation of unique circulating recombinant forms (CRFs) protection in humans. Such information regarding vaccine induced as a result of recombination among viruses of different subtypes. protection will only result from trials involving humans. Although, there is much knowledge about the genetic variability present in HIV strains but it is not clear about the relationship that is Brief History of HIV vaccine development found between genetic variability and the vaccine induced protection against infection [10].
Load more

Recommended publications
  • Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues
    Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues September 1995 OTA-BP-H-163 GPO stock #052-003-01429-7 Recommended Citation: U.S. Congress, Office of Technology Assessment, Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues, OTA-BP-H-163 (Washington, DC: U.S. Government Printing Office, September 1995). oreword IDS researchers are investigating new vaccines that would prevent infection with HIV and reduce the spread of AIDS. Some have argued that product liabil- ity concerns have discouraged investment in HIV vaccine research and devel- opment. The purpose of this OTA background paper is to describe the current state of development of HIV vaccines, and to discuss what is known about adverse reac- tions that may occur. The background paper provides an overview of ethical issues that arise in the conduct of HIV vaccine trials. The report also discusses alternatives to the current product liability system to encourage the development of HIV vaccines and to fairly compensate those who are harmed as a result of adverse reactions to the vaccine. This background paper was prepared in response to a request from the Subcommittee on Health of the House Ways and Means Committee. It is eleventh in OTA’s series of studies on HIV-related issues. The preceding papers in this series were: Do Insects Transmit AIDS? (9/87), AIDS and Health Insurance: An OTA Survey (2/88), How Effective is AIDS Education? (6/88), The Impact of AIDS on the Kaiser Permanente Medical Care Program (Northern California Region) (7/88), How Has Federal Research on AIDS/HIV Disease Contributed to Other Fields? (4/90), The Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection (9/90), HIV in the Health Care Workplace (11/91), The CDC’s Case Definition of AIDS: Implications of the Proposed Revisions (8/92), Difficult-to-reuse Needles for the Prevention of HIV Infection Among Injecting Drug Abusers (10/92), and External Review of the Federal Centers for Disease Control and Prevention’s HIV Prevention Programs (9/94).
    [Show full text]
  • Coversheet for Thesis in Sussex Research Online
    A University of Sussex DPhil thesis Available online via Sussex Research Online: http://eprints.sussex.ac.uk/ This thesis is protected by copyright which belongs to the author. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Please visit Sussex Research Online for more information and further details Knowledge Accumulation and Vaccine Innovation: Lessons from Polio and HIV/AIDS Ohid Yaqub Doctor of Philosophy University of Sussex Submitted in September 2008 ii I hereby declare that this thesis has not been submitted, either in the same or different form, to this or any other university for a degree. Ohid Yaqub iii To my parents and Corinne, Two worlds that should not be separate. iv ACKNOWLEDGEMENTS This thesis was funded by the Economic and Social Research Council and supervised by Paul Nightingale. Paul is a supervisor who is extremely generous with his time, ideas and encouragement; and who manages to make academia look extremely fun. His energy and enthusiasm were most important to me when I really thought the ship was sinking. I cannot thank him enough and feel privileged to have worked with him. My first opportunity to pursue some of the ideas in this thesis was under the supervision of Ed Steinmueller and Aldo Geuna.
    [Show full text]
  • HIV/AIDS Technologies: a Review of Progress to Date and Current Prospects
    Working Paper No.6 HIV/AIDS Technologies: A review of progress to date and current prospects COMMISSIONED BY: aids2031 Science and Technology Working Group AUTHORED BY: KEITH ALCORN NAM Publications Disclaimer: The views expressed in this paper are those of the author(s) and do not necessarily reflect the official policy, position, or opinions of the wider aids2031 initiative or partner organizations aids2031 Science and Technology working group A review of progress to date and current prospects October 2008 Acronyms 3TC lamivudine ANRS Agènce Nationale de Récherche sur la Sida ART Antiretroviral therapy ARV Antiretroviral AZT azidothymidine or zidovudine bDNA branched DNA CDC US Centers for Disease Control CHER Children with HIV Early Antiretroviral therapy (study) CTL Cytotoxic T-lymphocyte D4T stavudine DSMB Data and Safety Monitoring Board EFV Efavirenz ELISA Enzyme Linked Immunosorbent Assay FDC Fixed-dose combination FTC Emtricitabine HAART Highly Active Antiretroviral Therapy HBAC Home-based AIDS care HCV Hepatitis C virus HPTN HIV Prevention Trials Network HSV-2 Herpes simplex virus type 2 IAVI International AIDS Vaccine Initiative IL-2 Interleukin-2 LED Light-emitting diode LPV/r Lopinavir/ritonavir MIRA Methods for Improving Reproductive Health in Africa trial MSF Médecins sans Frontières MSM Men who have sex with men MVA Modified vaccinia Ankara NIH US National Institutes of Health NRTI Nucleoside reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OBT Optimised background therapy PCR Polymerase
    [Show full text]
  • Developing a Vaccine Against HIV Infection
    Developing a vaccine against HIV infection KEY POINTS Researchers have been working on an HIV vaccine since the 1980s, but progress towards an effective vaccine has been much slower than anticipated. Finding at least a partially effective vaccine remains of critical importance for the HIV response. The biggest reduction in new infections would be achieved by a combination of PrEP, universal antiretroviral treatment for people already living with HIV, and a vaccine.1 An HIV vaccine is a more realistic prospect today than a decade ago and an optimistic forecast of HIV vaccine availability is that one might be available by 2030. Explore this page to find out more about the need for a vaccine against HIV, challenges in vaccine development, progress in developing a vaccine and achieving an effective vaccine for HIV. What is an HIV vaccine? Today, an effective vaccine against HIV does not exist. A vaccine that can prevent infection would teach the immune system to respond to HIV by making antibodies that can bind to the virus and stop it from infecting cells, or by promoting other immune responses that kill the virus. No vaccine is 100% effective, and this is likely to be the same for HIV. Some people who receive a vaccine will not respond strongly enough to the vaccine and will not be protected, as in the case of the seasonal flu vaccine. But finding at least a partially effective vaccine remains of critical importance for the HIV response, as all successful disease elimination strategies have included a vaccine among their arsenal. The need for a vaccine against HIV UNAIDS estimates that 1.8 million people became infected with HIV in 2017, 36.9 million people were living with HIV and 21.7 million were receiving antiretroviral therapy.
    [Show full text]
  • Status of HIV Vaccine Research & Development
    Status of HIV Vaccine Research & Development Wayne C. Koff, Ph.D. Chief Scientific Officer, IAVI Global Vaccine Immunization Research Forum Bethesda, Maryland March 4, 2014 HIV continues to devastate…. 35.3 million people living with HIV worldwide 2.3 million new infections in 2012 ; 2012 2008 6,300 new HIV infections daily 33 million 35.3 million 36 million AIDS-related deaths to date 2005 32 million Women bear the brunt of the epidemic, representing almost 60% of HIV-infected adults in Africa and half of adults worldwide 2000 28.5 million Since the beginning >70,000,000 HIV Infections 1995 18.5 million 1990 7.5 million people living with HIV Remarkable scale up of treatment; however, doesn’t solve problem. Lifetime treatment required and for every (1) person put on treatment, (2) are newly infected. THE WORLD NEEDS AN HIV VACCINE Source: Joint United Nations Programme on HIV/AIDS Public Health Impact: A Vaccine Is Needed to “Get Close to Zero” Cumulative infections avoided 2011-50 22.5M 16.0M New HIV Infections HIV New 7.4M * An illustrative vaccine with an assumed efficacy of 60%, not representative of any specific candidate in development. Coverage reaches 70% in generalized HIV/AIDS epidemics, 60% in concentrated epidemics. Potential impact of an AIDS vaccine as part of the UNAIDS Enhanced Investment Framework, IFE Modeling project – UNAIDS, Futures Institute, IAVI, AVAC [funded by USAID] 3 AIDS vaccine development: Scientific Challenges 1. HIV variability 2. Lack of an ideal animal model 3. Natural immunity fails to clear HIV 4. HIV is a retrovirus- integrates into the host genome- short window of opportunity to control 5.
    [Show full text]
  • HIV VACCINE RESEARCH and DEVELOPMENT CD8 Group
    GLOSSARY OF KEY HIV VACCINE TERMS Immunogenicity – when attributed to a test vaccine, defines the • Since 2001, USAID has contributed $134 million to help discover an HIV vaccine. Currently, USAID is committing annual product’s ability to cause the body to produce antibodies or T-cells funding of $28 million through 2011 for HIV vaccine R&D. that may protect against an infection, disease, or foreign substance. • USAID provides support for all phases of HIV vaccine applied R&D, infrastructure, and capacity building for clinical trial Innate Immunity – a relatively nonspecific response that protects conduct, public communications, and policy analysis through a partnership with the International AIDS Vaccine Initiative. against a whole class or type of invaders but does not generate USAID does not support basic research. TECHNICAL ISSUE BRIEF immune memory (see adaptive immune response). Killer T-cells – a group of T-cells that is activated by helper T-cells • USAID plans involvement with the Global HIV/AIDS Vaccine Enterprise. PATHWAYS OF DISCOVERY: and has the ability to destroy cells infected by foreign invaders (such as viruses). Also known as cytotoxic T-cells, they may belong to the • USAID facilitates coordination between HIV vaccine clinical trial activities and HIV/AIDS prevention, care, and treatment HIV VACCINE RESEARCH AND DEVELOPMENT CD8 group. programs in developing countries. Lymphocytes – the diverse set of white blood cells (each with different functions) that are responsible for immune responses. virologists convenes twice a year to review the R&D portfolio activities. As the Global HIV/AIDS Vaccine Enterprise evolves Introduction There are two main types: B-cells (responsible for producing anti- under consideration by the organization.
    [Show full text]
  • Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward
    AIDS PATIENT CARE and STDs Volume 29, Volume 7, 2015 ª World Health Organization 2015 DOI: 10.1089/apc.2014.0348 Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward Ying-Ru Lo, MD,1 Carissa Chu, BS,2,3 Jintanat Ananworanich, MD, PhD,4,5 Jean-Louis Excler, MD,4,5 and Joseph D. Tucker, MD, PhD, MA3,6 Abstract Clinical and basic science advances have raised considerable hope for achieving an HIV cure by accelerating research. This research is dominated primarily by issues about the nature and design of current and future clinical trials. Stakeholder engagement for HIV cure remains in its early stages. Our analysis examines timing and mechanisms of historical stakeholder engagement in other HIV research areas for HIV-uninfected indi- viduals [vaccine development and pre-exposure prophylaxis (PrEP)], and HIV-infected individuals (treatment as prevention, prevention of mother-to-child transmission, and treatment of acute HIV infection) and articulate a plan for HIV cure stakeholder engagement. The experience from HIV vaccine development shows that early engagement of stakeholders helped manage expectations, mitigating the failure of several vaccine trials, while paving the way for subsequent trials. The relatively late engagement of HIV stakeholders in PrEP research may partly explain some of the implementation challenges. The treatment-related stakeholder engagement was strong and community-led from the onset and helped translation from research to implementation. We outline five steps to initiate and sustain stakeholder engagement in HIV cure research and conclude that stakeholder engagement represents a key investment in which stakeholders mutually agree to share knowledge, benefits, and risk of failure.
    [Show full text]
  • Px Wire: on HIV Prevention Research Volume 1 | No
    A Quarterly Update Px Wire: on HIV Prevention Research Volume 1 | No. 4 October–December 2008 and Phambili studies. The initial results of the Step study AVAC’s Take were published in November 2008 in the Lancet journal (Lancet, doi:10.1016/S0140-6736(08)61591-3). Greetings! This is the last issue of Px Wire in 2008—and what In the Step study, MRK-Ad5 had no overall benefit in terms a year it has been. The AIDS vaccine field has started to move Continues on back ahead with different goals and refined strategies in the wake of disappointing data from 2007. Multiple PrEP trials were launched or expanded, the microbicide field began to focus considerably At a Glance: Moving right along more on the implications of ARV-containing products, and the scale-up of male circumcision started in some countries. • An FDA panel of independent advisors recommended At the International AIDS Conference in August, and approval of the newly formulated female condom (FC2) in a provocative Lancet article (Lancet, doi:10.1016/S0140- in December, green-lighting the less expensive and 6736(08)61697-9) by WHO staff, including Kevin De Cock, physically streamlined second-generation product by director of the HIV/AIDS program, the notion of ARV the Female Health Company. Donors, governments and treatment as prevention seized the spotlight. This newly implementers should take advantage of this lower cost highlighted strategy will continue, we predict, to help shape option and take long overdue action to dramatically the field in 2009. increase access to and information about the female Also in 2009, AVAC will work with other prevention stakeholders condom as part of all HIV prevention and family to put the spotlight on HIV testing, which is the cornerstone planning programs.
    [Show full text]
  • 2012 NIAID Jordan Report
    THE JORDAN REPORT ACCELERATED DEVELOPMENT OF VACCINES 2012 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases Images on cover, from the top: Courtesy of the US Centers for Disease Control and Prevention; istock.com; Courtesy of the National Library of Medicine; Courtesy of MedImmune THE JORDAN REPORT ACCELERATED DEVELOPMENT OF VACCINES 2012 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases NIH Publication No. 11-7778 January 2012 www.niaid.nih.gov ADDITIONAL RESOURCES National Institute of Allergy and Infectious Diseases, www.niaid.nih.gov Vaccines.gov: your best shot at good health, www.vaccines.gov Centers for Disease Control and Prevention: Immunization Schedules, www.cdc.gov/vaccines/recs/schedules/ Table of Contents INTRODUCTION VACCINE UPDATES Foreword by Anthony S. Fauci, M.D. ......................................... 3 Dengue M. Cristina Cassetti, Ph.D. .......................................................... 95 Tribute by Carole A. Heilman, Ph.D. ......................................... 5 HIGHLIGHT BOX Vaccine Against Chikungunya Virus in Development EXPERT ARTICLES Gary J. Nabel, M.D., Ph.D. and Ken Pekoc ......................... 97 Vaccinomics and Personalized Vaccinology Severe Acute Respiratory Syndrome Gregory A. Poland, M.D., Inna G. Ovsyannikova, Ph.D. and Frederick J. Cassels, Ph.D. ............................................................ 98 Robert M. Jacobson, M.D. .............................................................11 HIGHLIGHT BOX Sex Differences in Immune Responses to Vaccines Vaccine Delivery Technologies Col. Renata J. M. Engler, M.D. and Mary M. Klote, M.D. ....... 19 Martin H. Crumrine, Ph.D. ................................................. 105 Immunization and Pregnancy West Nile Virus Flor M. Munoz, M.D. .................................................................. 27 Patricia M. Repik, Ph.D.
    [Show full text]
  • Report of the WHO-UNAIDS Vaccine Advisory Committee (VAC) Geneva, May 1-3, 2012
    Report of the WHO-UNAIDS Vaccine Advisory Committee (VAC) and Scientific Briefing on the biomedical HIV/AIDS prevention landscape and consequences for HIV vaccine development Geneva, May 1-3, 2012 Contents page Introduction & Background 2 PART ONE (Scientific Briefing) 1. Biomedical prevention of HIV by non-vaccine approaches 4 2. The vaccine trial landscape 5 3. Implications for HIV vaccine trials 7 4. Combining interventions 10 5. Developing a global advocacy roadmap for HIV prevention 13 PART TWO (VAC Report) 15 Conclusions and Recommendations 22 1 Introduction This report is a summary record of the WHO/UNAIDS HIV Vaccine Advisory Committee (VAC) meetings on 1-3 May 2012, including the scientific briefing on the biomedical HIV/AIDS prevention landscape and consequences for HIV vaccine development In addition to summarizing the scientific presentations and discussions, this report also reflects the VAC efforts to formulate a related WHO workplan for 2012-2013. This includes building consensus about the main issues, and demonstrating to Member States the important role WHO has in HIV vaccine development and the added value that WHO has in this endeavour. Finally, this report puts forward a list of recommendations for action drawn from the proceedings, The report is structured in two main parts: (1) the scientific presentations in plenary on the first and second days of the meeting; and (2) the VAC closed session on the third and final day in which those presentations and discussions, augmented by further presentations from representatives of invited groups and networks, formed the basis for shaping the workplan and producing recommendations. Background Almost thirty years after HIV was first identified, the virus still ravages the world.
    [Show full text]
  • W, a COMPARISON of KNOWLEDGE and ATTITUDES BETWEEN
    * NB /w, A COMPARISON OF KNOWLEDGE AND ATTITUDES BETWEEN DIRECTORS OF ATHLETICS AND HEAD TRAINERS IN THE SOUTHWEST AND SOUTHLAND CONFERENCES REGARDING HIV-TRANSMISSION ISSUES IN ATHLETICS DISSERTATION Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY By Harold L. Whiteley, B.S., M.S. Denton, Texas December, 1995 * NB /w, A COMPARISON OF KNOWLEDGE AND ATTITUDES BETWEEN DIRECTORS OF ATHLETICS AND HEAD TRAINERS IN THE SOUTHWEST AND SOUTHLAND CONFERENCES REGARDING HIV-TRANSMISSION ISSUES IN ATHLETICS DISSERTATION Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY By Harold L. Whiteley, B.S., M.S. Denton, Texas December, 1995 Whiteley, Harold L., A comparison of knowledge and attitudes between directors of athletics and head trainers in the Southwest and Southland conferences regarding HIY-transmission issues in athletics. Doctor of Philosophy (Higher Education), December, 1995, 326 pp., 13 tables, references, 295 titles. The purpose of this study was to investigate and compare knowledge and attitudes of directors of athletics and head trainers in the Southwest (Division 1 A) and the Southland (Division 1AA) Conferences concerning HIV/AIDS issues related to transmission, prevention, and protection within college athletics programs. The results of this qualitative study provided descriptive data from university administrators within the athletics setting who are responsible for providing adequate student athlete health care services from developed and implemented administrative policies that directly or indirectly affect a student athlete's physiological and psychological well-being.
    [Show full text]
  • Evaluation of CD8+ T Cell Responses Towards Conserved HIV-1 Epitopes
    Evaluation of CD8+ T cell responses towards conserved HIV-1 epitopes in naturally infected and vaccinated individuals Ambreen Ashraf Section of Immunology Division of Infectious Diseases Department of Medicine Imperial College London This Thesis was submitted to Imperial College for the Degree of Doctor of Philosophy January 2017 Declaration of Originality I hereby declare that all the work illustrated in this thesis signifies my novel work and was performed in the laboratories of International AIDS Vaccine Initiative, Department of Immunology, Imperial College of Science, Technology and Medicine, London and has not been submitted to any other institution. Furthermore, I have used no other source of information except those which are notified by citations. Ms Ambreen Ashraf 2 Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistributions, researchers must make clear to others the licence terms of this work. 3 Abstract of thesis Human Immunodeficiency Virus (HIV) infection is a global public health priority. An effective HIV- 1 vaccine strategy must overcome the enormous genetic diversity generated by the virus while inducing potent, long lasting immune responses. In this thesis, virus-specific cellular immune responses directed towards HIV conserved regions were evaluated using a validated IFN-γ enzyme- linked immunospot (ELISpot) assay and two sets of peptide panels based upon HIV-1 vaccine candidates.
    [Show full text]